Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Eµ-TCL1 Transgenic Mouse Model

The Eµ-TCL1 transgenic mouse model represents the most widely and extensively used animal model for chronic lymphocytic leukemia (CLL). In this report, we performed a meta-analysis of leukemia progression in over 300 individual Eµ-TCL1 transgenic mice and discovered a significantly accelerated disease progression in females compared to males. This difference is also reflected in an aggressive CLL mouse model with additional deletion of Tp53 besides the TCL1 transgene. Moreover, after serial adoptive transplantation of murine CLL cells, female recipients also succumbed to CLL earlier than male recipients. This sex-related disparity in the murine models is markedly contradictory to the human CLL condition. Thus, due to our observation we urge both careful consideration in the experimental design and accurate description of the Eµ-TCL1 transgenic cohorts in future studies.

[1]  D. Lang,et al.  Differences in tumor initiation and progression of melanoma in the BrafCA;Tyr‐CreERT2;Ptenf/f model between male and female mice , 2020, Pigment cell & melanoma research.

[2]  M. Hallek.  Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment , 2019, American journal of hematology.

[3]  M. Fiorenza,et al.  The TCL1 function revisited focusing on metabolic requirements of stemness , 2019, Cell cycle.

[4]  Lisa L. Smith,et al.  Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma , 2019, Clinical Cancer Research.

[5]  R. Shansky.  Are hormones a “female problem” for animal research? , 2019, Science.

[6]  Angela N. Brooks,et al.  A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. , 2019, Cancer cell.

[7]  M. Hallek,et al.  New roles for B cell receptor associated kinases: when the B cell is not the target , 2019, Leukemia.

[8]  P. Lichter,et al.  Rejection of adoptively transferred Eµ-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines , 2019, Leukemia.

[9]  Xiangyin Kong,et al.  Sex-related DNA methylation differences in B cell chronic lymphocytic leukemia , 2019, Biology of Sex Differences.

[10]  J. Byrd,et al.  PI3K p110&dgr; inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression , 2018, The Journal of clinical investigation.

[11]  S. Ponnazhagan,et al.  Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations , 2018, Laboratory Investigation.

[12]  R. Greil,et al.  Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development , 2018, Leukemia.

[13]  C. Guillemette,et al.  Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients , 2018, Annals of hematology.

[14]  T. Shanafelt,et al.  Chronic lymphocytic leukaemia , 2018, The Lancet.

[15]  A. Wiestner,et al.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances , 2018, Nature Reviews Cancer.

[16]  M. Peifer,et al.  Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia , 2017, Nature Communications.

[17]  Steve D. M. Brown,et al.  Prevalence of sexual dimorphism in mammalian phenotypic traits , 2017, Nature Communications.

[18]  A. Kurisaki,et al.  A Role for KLF4 in Promoting the Metabolic Shift via TCL1 during Induced Pluripotent Stem Cell Generation , 2017, Stem cell reports.

[19]  M. Hallek,et al.  LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia. , 2016, Cancer cell.

[20]  F. Cheng.  Gender Dimorphism Creates Divergent Cancer Susceptibilities. , 2016, Trends in cancer.

[21]  Krishna R. Kalari,et al.  Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. , 2016, Molecular endocrinology.

[22]  G. Russo,et al.  TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia , 2016, Cell Death and Disease.

[23]  U. Klein,et al.  Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. , 2014, Blood.

[24]  D. Catovsky,et al.  The clinical significance of patients’ sex in chronic lymphocytic leukemia , 2014, Haematologica.

[25]  Francis S Collins,et al.  Policy: NIH to balance sex in cell and animal studies , 2014, Nature.

[26]  G. Fingerle-Rowson,et al.  CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. , 2013, Blood.

[27]  G. Fingerle-Rowson,et al.  Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. , 2013, Blood.

[28]  A. Kohlmann,et al.  Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo , 2013, Cancer cell.

[29]  Michael A. Freitas,et al.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL) , 2012, Proceedings of the National Academy of Sciences.

[30]  Suzanne R. Thibodeaux,et al.  B7-H1–Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses , 2010, The Journal of Immunology.

[31]  S. Leung,et al.  Biomarkers , Genomics , Proteomics , and Gene Regulation Subcellular Localization of Activated AKT in Estrogen Receptor-and Progesterone Receptor-Expressing Breast Cancers Potential Clinical Implications , 2010 .

[32]  Andrea Califano,et al.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.

[33]  J. Byrd,et al.  Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia , 2009, Proceedings of the National Academy of Sciences.

[34]  J. Kurie,et al.  A genetic mouse model for metastatic lung cancer with gender differences in survival , 2007, Oncogene.

[35]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[36]  Lisa L. Smith,et al.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. , 2006, Blood.

[37]  C. Croce,et al.  B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Molica.  Sex differences in incidence and outcome of chronic lymphocytic leukemia patients , 2006, Leukemia & lymphoma.

[39]  C. Croce,et al.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Foà,et al.  Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.

[41]  Y. Pekarsky,et al.  The long journey of TCL1 transgenic mice: lessons learned in the last 15 years. , 2015, Gene expression.